Feinberg: Genesis CTO Sergey Edunov led Meta's Llama 2 research team
Evan Feinberg · 🔬 "The Most Innovative Diffusion Research Is Happening in Drug Discovery, Not Image Generation" · Jun 30, 2026 · at 20:36
Evan Feinberg introduces Genesis CTO Sergey Edunov and references his background leading LLM pretraining at Meta.
0:00 / 0:05exact quote · 5.4s
▶ Watch the full episode on YouTube → 720p mp4 · rendered on demand · StarZero watermark
“Sergei led the LLAMA II research team at Meta when he was still there.”
quote is from the automated transcript, cleaned for reading: filler sounds and stutters are removed, nothing is rephrased. names can be misheard (the analysis reads context, assessments check outside sources). how →
More from Evan Feinberg
Feinberg: Studies show AlphaFold structures provided no value for drug docking
“There is this, ah, a few papers that came out, one was in Cell, I think last year, which showed that for all of the claims about AlphaFold-solving drug discovery, people try to take AlphaFold-produced protein structures, use them for traditional docking, and f…”
Feinberg: The most innovative diffusion research is happening in 3D structure prediction
“What's kind of cool is right now for people that are interested in really core fundamental AI research, actually some of the most innovative diffusion research is happening in our field, is happening in three D structure prediction right now.”
Feinberg: High-throughput screening exhibits a shockingly low R-squared to actual synthesis
“The reality is that the translation of high throughput screens, whether it's Dell, DNA encoded libraries, or more traditional screens, the R-squared of those predictions to, like, the actual business of resynthesizing a molecule de novo and doing a Low through…”
Feinberg: Robotic lab automation trades off molecule novelty and quality for speed
“The kinds of chemistries that today can be automated are fairly constrained. And so your ability to search chemical space broadly for those really top top Pareto optimal compounds is, is actually very limited. So the benefits you get in speed have a very harsh…”
Feinberg: Chipmakers will invest in life sciences as LLM alpha shrinks
“I do think that chip makers, including Nvidia, are going to want to get a lot more invested in life sciences because it will always be high in demand. And The amount of alpha left in pure LLM space is just getting a little questionable.”